BML , Inc.

BML , Inc.

21.80
EUR
+0.20
(+0.93%)
824.64MMarket Cap
Nov 11Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
2,331.82
2,457.93
2,566.51
2,618.56
2,669.04
2,750.18
2,864.53
3,410.21
4,594.86
4,051.85
3,539.64
3,672.26
3,947.38
- -
Basic EPS, GAAP
117.48
91.2
127.69
140.01
140.81
156.05
151.26
337.43
833.22
395.83
154.81
160.62
203.54
- -
Free Cash Flow per Basic Share
183.91
190.53
214.62
166.52
186.36
203.57
205.57
378.43
951.19
134.21
-166.28
-21.77
278.23
- -
Dividend per Share
19.99
27.5
32.49
32.48
34.97
36.49
39.41
44.99
85.32
126.13
100.06
89.99
130.8
- -
Book Value per Share
1,301.79
1,396.68
1,465.38
1,584.9
1,705.07
1,810.94
1,874.79
2,175.31
2,910.1
3,139.16
3,228.6
3,317.39
3,405.89
- -
Tangible Book Value per Share
1,202.7
1,286.42
1,380.61
1,502.34
1,617.84
1,727.2
1,775.36
2,081.65
2,810.6
3,022.76
3,105.67
3,189.54
3,280.63
- -
Basic Weighted Avg Shares
42
42
42
42
43
43
42
41
40
39
39
39
38
38
Sales/Revenue/Turnover
99,047
104,404
109,024
111,243
113,502
117,129
120,732
138,571
186,067
159,462
137,964
143,191
150,262
- -
Operating Margin (%)
8.27
6.68
7.73
8.39
8.23
8.92
8.09
14.39
26.28
15.01
6.64
6.54
6.94
- -
Depreciation Expense
5,490
5,979
5,763
5,160
5,331
5,020
5,043
5,365
5,801
6,257
6,700
7,716
9,121
- -
Net Income, GAAP
4,990
3,874
5,424
5,948
5,988
6,646
6,375
13,711
33,741
15,578
6,034
6,263
7,748
- -
Effective Tax Rate (%)
37.57
41.31
33.57
32.72
34.22
34.15
33.18
31.99
31.1
33.19
34.23
32.71
33.18
- -
Profit Margin (%)
5.04
3.71
4.98
5.35
5.28
5.67
5.28
9.89
18.13
9.77
4.37
4.37
5.16
- -
Working Capital
26,533
29,515
35,348
39,960
44,081
49,554
47,574
58,543
85,048
87,494
73,329
64,664
60,820
- -
LT Debt
2,286
2,131
1,983
2,139
2,048
2,257
2,200
2,037
2,136
2,787
3,732
3,659
3,170
- -
Total Equity
57,654
61,966
65,205
70,644
76,220
81,124
80,420
93,121
121,681
126,748
130,137
133,770
132,126
- -
Return on Invested Capital (%)
8.37
6.31
8.19
8.61
7.83
8.2
7.59
14.47
28.1
11.88
4.51
4.55
4.97
- -
Return on Capital (%)
7.87
5.63
7.52
7.76
7.27
7.53
7.1
14.61
29.66
11.74
4.41
4.44
5.48
- -
Return on Common Equity (%)
9.4
6.76
8.92
9.18
8.56
8.88
8.32
16.66
32.98
13.05
4.86
4.91
6.03
- -

Capital Structure

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
ST Debt
- -
1,646
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
3,170
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
37
37
37
Market Capitalization
135,286
151,262
135,057

Working Capital

JPY

•

in mil. unless spec.
Sep'26
Mar'26
Jun'27
Total Current Assets
98,859
101,707
- -
Cash, Cash Equivalents & STI
64,997
68,029
- -
Accounts Receivable, Net
27,515
26,827
- -
Inventories
4,738
4,843
- -
Total Current Liabilities
37,839
40,887
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
1,646
- -
Deferred Revenue
- -
- -
- -

Growth Rates

JPY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.66%
7.81%
-1.23%
Free Cash Flow
-151.64%
-318.57%
-1,347.47%
Net Income, GAAP
19.08%
11.7%
23.71%
Sales/Revenue/Turnover
4.04%
3.05%
4.94%
Total Cash Common Dividend
- -
28.62%
41.89%

Quarterly Revenue

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
143,191
2026
- -
- -
- -
- -
150,262
2027
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
160.62
2026
- -
- -
- -
- -
203.54
2027
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

JPY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
89.99
2026
- -
- -
- -
- -
130.8
2027
- -
- -
- -
- -
- -

Company Description

CEO
Kensuke Kondo
Full Time Employees
4,612
Sector
Health services
Industry
Medical/Nursing services
Address
5-21-3 Sendagaya Tokyo TY Japan 151-0051
IPO Date
Apr 25, 2001
Website
bml.co.jp
Business
BML, Inc. (4694.T) provides clinical laboratory testing services and related offerings to medical institutions throughout Japan. The company offers routine biochemical and hematological tests; special tests including tumor markers, infectious diseases, hormones, cellular immunity, genetics, and bacteriology; microbiological testing for food sanitation and environmental analysis; automated systems such as Frontier for pre-testing specimen sorting and dispensing and Symphony for chemistry and hematology analysis; medical information systems encompassing electronic medical charts and laboratory information systems; genome analysis services; and additional services like food sanitation testing, environmental hygiene monitoring, and pharmaceutical consulting. Founded in 1955 and headquartered in Tokyo, BML operates a nationwide network of over 100 sales offices, regional laboratories, and the central BML General Laboratory, processing tests for approximately 300,000 patients daily across more than 4,000 items. The company maintains rigorous quality controls with ISO 15189 accreditation for its general laboratory and ISO 27001 for information security, serving hospitals, clinics, and pharmaceutical entities primarily within Japan. Recent developments include ongoing enhancements to next-generation sequencing technologies for genomic testing in infectious diseases, cancer, and hereditary conditions, alongside expansions in automation and regional laboratory networks to bolster community-based services.